Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Blood|July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialMarinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup studyMarinus H J van Oers, Evelyn Tönnissen, Martine Van Glabbeke, et al.
American Journal of Hematology|February 1, 2014
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trialMark Hertzberg, Jane Palfrey Matthews, Janey Malka Stone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaMaher K Gandhi, Eleanore Lambley, Jacqueline Burrows, et al.
Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.
The Lancet. Oncology|April 11, 2008
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) studyMichael Pfreundschuh, Anthony D Ho, Eva Cavallin-Stahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialPatrice Carde, Matthias Karrasch, Catherine Fortpied, et al.
Pageof 16